COMP360 psilocybin treatment in TRD
The New England Journal of Medicine publishes results from phase 2b trial of investigational COMP360 psilocybin treatment for treatment-resistant depression
About the phase 2b trial
Our randomised controlled phase 2b study of investigational psilocybin treatment in treatment-resistant depression is the largest psilocybin treatment clinical trial ever conducted, with 233 patients across 22 sites in 10 countries across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin treatment in three doses: 1mg, 10mg, 25mg. The results, published in the New England Journal of Medicine, show that a single 25mg dose of COMP360 psilocybin, in combination with psychological support, was associated with a highly statistically significant reduction in depressive symptoms after three weeks (p<0.001), with a rapid and durable response for up to 12 weeks.
About the NEJM publication
Our phase 2b study, which has been published in the New England Journal of Medicine, has informed our clinical development programme for COMP360 psilocybin treatment.
Learn more
Find out more about our COMP360 psilocybin treatment in TRD.
*Professor Allan Young was the Principal Investigator on Compass Pathways’ phase 2b trial site at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London and Coordinating Principal Investigator for the UK
**Professor David Hellerstein was the Principal Investigator on Compass Pathways’ phase 2b trial site at Columbia University, New York